BIO-KEY INTERNATIONAL INC (BKYI)
NASDAQIndustrialsInformation Technology ServicesSnapshot 2026-09-04
$2.81-0.35%
Close 2026-09-04 · 1-day change
NASDAQIndustrialsInformation Technology ServicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Resolve Nasdaq listing suspension: Nasdaq delisting notice active (June 2026) vs resolved by 2026-Q2.
Revenue is growing fast, aiming for $5 million in first half 2026. Losses are shrinking, with net loss down to about $205,000 in Q1 2026. Management is working to fix Nasdaq listing problems. These show the company is improving.
The company is still losing money and faces Nasdaq delisting risks. Revenue is small and uncertain. The stock has fallen over 36% from its high. These risks could stop a recovery.
The market expects about 6% revenue growth. Our fair value is $11.35, but the stock trades 62% below consensus price. We see risk from ongoing losses and listing issues.
Breaks if: Nasdaq delisting occurs or suspension continues past 2026-Q2
Regain compliance with Nasdaq listing rules and restore trading on Nasdaq Capital Market.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story, as BKYI is working to improve its financial performance after a period of losses. The current thesis state is cautious, reflecting recent volatility and weak results.
The market seems to have priced in a low level of fragility, as there are no immediate concerns triggering significant risk. Valuation appears cheap compared to peers, but there is an expectations gap indicating that the market is not fully optimistic about BKYI's recovery.
Management is focused on growing revenues and improving operating income, with recent results showing some progress in reducing net losses. However, the overall financial performance remains weak, and the high-risk environment could impact future results.
The long-term thesis hinges on BKYI's ability to meet its revenue growth targets and improve profitability. Additionally, the performance of sector bellwethers will be crucial, as their success or failure could influence BKYI's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. License revenue surged 53% in the second quarter. The company also targets profitability in the second half of 2026. These factors align with improving operating income and reducing net losses. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated or referenced in 3 disclosures including 2026-Q2. The company received Nasdaq non-compliance notices in early 2026 but regained compliance and resumed Nasdaq trading on July 8, 2026. The trajectory shows resolution of the listing suspension consistent with management's stated priority.
“Nasdaq Listing: BIO-key completed a 1-for-10 reserve stock split and regained compliance with Nasdaq listing rules in July.”
Breaks if: net loss worsens beyond -$4.29 million in next quarters
Focus on financial discipline to reduce operating losses and net losses while improving gross margin and controlling expenses.
Stated as a priority in 2 of last 2 quarters. Net loss improved from $(737K) in 2026-Q1 to $(165K) and from $(1.2M) in 2025-Q2 to $(577K) in 2026-Q2, a 51% reduction. Operating expenses decreased 5% in Q2'26 vs. Q2'25. The trajectory shows delivering improved operating income and reduced net losses consistent with management's stated priority.
“Q2'26 net loss trimmed by 51% to $(577K) vs. $(1.2M) in Q2'25; operating expenses decreased 5%.”
“Q1'26 net loss improved to $(165K) vs. $(737K) in Q1'25; operating expenses decreased 4%.”
Breaks if: total revenue in 1H 2026 falls below $3.3 million
Achieve significant revenue growth in 1H 2026 driven by license fees and hardware sales, targeting continued growth in 2H 2026.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $1.61M in 2025-Q1 to $2.15M in 2026-Q1 (+34%) and from $1.7M in 2025-Q2 to $1.92M in 2026-Q2 (+13%). Guidance expects 1H'26 revenues to rise 50% to approx. $5M vs. 1H'25 $3.3M and targets growth and profitability in 2H'26. The trajectory shows delivering revenue growth consistent with management's stated priority.
“BIO-key targets revenue growth and profitability for the 2H'26.”
“1H'26 revenues expected to rise 50% to approx. $5M vs. $3.3M in 1H'25.”
In the next 1 to 3 years, BKYI's trajectory will depend on management's execution and external market conditions. Not investment advice.